In contrast, AAC2 treatment promoted the expression of inhibitory synaptic genes, Syn2 (synapsin II) and Syp (synaptophysin), examined in the context of vesicular trafficking of neurotransmitters [85], and mutation (T198I) is associated with epilepsy and intellectual disability [86]. Here, SYN2 is linked to epilepsy.